基因載體市場：按載體類型、有效載荷類型、應用、疾病領域、遞送管道、遞送方式、最終用戶和地區分類

預計到2026年，基因載體市場規模將達到105.6億美元，到2033年將達到246.8億美元。預計從2026年到2033年，其複合年成長率將達到12.9%。

全球基因載體市場是生物技術和製藥行業的重要組成部分，涵蓋了旨在將治療性遺傳物質輸送到目標細胞以治療各種疾病的先進遞送系統。基因載體作為一種媒介，可以將包括DNA、RNA和其他核酸在內的遺傳物質導入患者細胞，以糾正遺傳缺陷、增強免疫反應或遞送治療性蛋白質。

該市場涵蓋多種類型的載體，例如病毒載體（腺病毒、慢病毒、逆轉錄病毒、腺結合病毒）、非病毒載體（脂質體轉染、電穿孔、顯微注射）以及新興的混合系統。隨著遺傳性疾病、癌症和罕見疾病的日益普遍，對創新基因治療方案的需求顯著成長，基因載體已成為個人化醫療方法中不可或缺的關鍵要素。

受基因治療研究投入增加、基因治療方法獲得監管部門批准以及載體工程技術進步的推動，該市場正經歷顯著成長。領先的製藥公司、生技公司和研究機構正積極開發新型載體系統，以提高遞送效率、降低免疫抗原性並增強治療效果，從而拓展該市場在腫瘤學、眼科學、免疫學和罕見疾病應用領域的潛力。

市場動態

全球基因載體市場受多種關鍵因素驅動，其中包括全球遺傳疾病和癌症發病率的不斷上升。這些因素促使人們尋求創新的治療方法，而基因載體恰好能夠滿足這項需求。對基因治療研發的大量投資，以及政府和創業投資的持續增加，正在加速市場成長。

近期監管部門的批准，例如基因治療相關臨床試驗的增加以及美國FDA批准多種基因治療產品，正在創造有利的市場環境。載體工程技術的進步，包括標靶特異性的提高和免疫抗原性的降低，正在增強治療效果和病人安全性。然而，市場仍面臨諸多限制因素，主要是基因載體研發和生產的高成本，限制了其可近性和商業性可行性。

複雜的監管要求和漫長的核准流程構成了市場准入和產品商業化的障礙。病毒載體引發的免疫反應、潛在的插入突變以及長期影響等安全隱患仍然是市場接受度面臨的挑戰。此外，載體設計方面的技術難題，例如有效載荷容量限制和組織特異性靶向的困難，也限制了其治療應用。儘管如此，市場格局中仍蘊藏著巨大的機會。

基因載體在治療治療選擇有限的罕見疾病方面的應用日益廣泛，展現出巨大的成長潛力。亞太和拉丁美洲等新興市場由於醫療基礎設施的改善和公眾意識的提高，蘊藏著巨大的未開發潛力。製藥公司和生物技術公司之間的合作正在推動創新和市場擴張。新一代載體的研發，包括安全性更高、遞送能力更強的載體，以及能夠降低生產成本的製造技術的進步，都為市場參與企業帶來了巨大的成長機會。

本研究的關鍵特徵

• 本研究確定了各個細分市場的潛在商機，並說明了該市場具有吸引力的投資提案矩陣。
• 此外，本研究還深入分析了市場促進因素、限制因素、機會、新產品發布和批准、市場趨勢、區域展望以及主要參與者採取的競爭策略。
• 本研究根據以下參數創建了全球基因載體市場主要公司的概況：公司亮點、產品系列、關鍵亮點、財務表現和策略。
• 透過利用本報告中的見解，企業行銷負責人和經營團隊可以就未來的產品發布、產品升級、市場擴張和行銷策略做出明智的決策。
• 全球基因載體市場報告的目標受群眾外包括該行業的各類相關人員，例如投資者、供應商、產品製造商、經銷商、新參與企業和金融分析師。
• 相關人員可以透過分析全球基因載體市場中使用的各種策略矩陣輕鬆做出決策。

目錄

第1章：研究目標與前提條件

• 分析目的
• 先決條件
• 簡稱

第2章 市場展望

• 報告說明
  • 市場定義和範圍
• 執行摘要

第3章：市場動態、監管與趨勢分析

• 市場動態
• 促進因素
• 抑制因子
• 機會
• 影響分析
• 監管趨勢
• 產品上市及核准
• PEST分析
• 波特的分析
• 併購情景
• 產業趨勢

第4章 全球基因載體市場：依載體類型分類，2021-2033年

• 病毒載體
• 非病毒載體

第5章 全球基因載體市場：依酬載類型分類，2021-2033年

• DNA載體
• RNA載體
• siRNA/shRNA載體
• CRISPR/Cas 組件
• 反義寡核苷酸
• mRNA載體

第6章 全球基因載體市場：依應用領域分類，2021-2033年

• 基因替代療法
• 基因轉移和增強療法
• 基因靜默/敲除
• 基因編輯（CRISPR、ZFN、TALEN）
• 細胞療法生產（CAR-T，基因改造的NK/T細胞）
• 疫苗（用於預防和治療）
• 僅供研究使用（臨床前體外/體內工具）

第7章 全球基因載具市場：依疾病領域分類，2021-2033年

• 腫瘤學
• 神經病學
• 心血管/代謝
• 眼科
• 血液/免疫系統
• 感染疾病
• 肌肉骨骼系統與遺傳性肌肉疾病
• 皮膚科和傷口護理
• 其他罕見遺傳疾病

第8章 全球基因載體市場：依遞送管道分類，2021-2033年

• 靜脈
• 肌肉內部
• 皮下
• 椎管內腔
• 腫瘤內部
• 眼科
• 吸入
• 其他

第9章 全球基因載體市場：依遞送方式分類，2021-2033年

• 體內遞送
• 體外遞送

第10章 全球基因載具市場：依最終用戶分類，2021-2033年

• 生物製藥和生物技術公司
• CDMO/CMO（合約開發與生產組織）
• 學術研究機構
• 政府和非營利研究機構
• 在醫院內和專門的基因治療中心

第11章 全球基因載體市場：依地區分類，2021-2033年

• 北美洲
  • 美國
  • 加拿大
• 拉丁美洲
  • 巴西
  • 阿根廷
  • 墨西哥
  • 其他拉丁美洲國家
• 歐洲
  • 德國
  • 英國
  • 西班牙
  • 法國
  • 義大利
  • 俄羅斯
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國
  • ASEAN
  • 其他亞太國家
• 中東
  • GCC
  • 以色列
  • 其他中東國家
• 非洲
  • 南非
  • 北非
  • 中非

第12章 競爭格局

• Lonza Group
• Thermo Fisher Scientific
• Catalent Inc
• Oxford Biomedica
• FUJIFILM Diosynth BIoTechnologies
• Advanced Therapies, LLC.
• Aldevron
• AGC Biologics
• SIRION BIoTech
• FinVector
• Merck KGaA
• uniQure
• Charles River Laboratories
• Takara Bio

第13章 分析師建議

• 機會分析
• 分析師意見
• 一致的機會地圖

第14章 參考文獻與調查方法

• 參考
• 調查方法
• 關於本公司

Gene Vector Market is estimated to be valued at USD 10.56 Bn in 2026 and is expected to reach USD 24.68 Bn by 2033, growing at a compound annual growth rate (CAGR) of 12.9% from 2026 to 2033.

The global gene vector market represents a pivotal segment within the biotechnology and pharmaceutical industries, encompassing sophisticated delivery systems designed to transport therapeutic genetic material into target cells for treatment of various diseases. Gene vectors serve as vehicles that facilitate the introduction of genetic material, including DNA, RNA, and other nucleic acids, into patient cells to correct genetic defects, enhance immune responses, or provide therapeutic proteins.

This market encompasses various vector types including viral vectors (adenovirus, lentivirus, retrovirus, adeno-associated virus), non-viral vectors (lipofection, electroporation, microinjection), and emerging hybrid systems. The growing prevalence of genetic disorders, cancer, and rare diseases has significantly amplified the demand for innovative gene therapy solutions, positioning gene vectors as critical components in personalized medicine approaches.

The market has witnessed substantial growth driven by increasing investments in gene therapy research, regulatory approvals for gene-based treatments, and technological advancements in vector engineering. Major pharmaceutical companies, biotechnology firms, and research institutions are actively developing novel vector systems to improve delivery efficiency, reduce immunogenicity, and enhance therapeutic outcomes, thereby expanding the market's potential across oncology, ophthalmology, immunology, and rare disease applications.

Market Dynamics

The global gene vector market is propelled by several key drivers, including the rising incidence of genetic disorders and cancer worldwide, which necessitates innovative therapeutic approaches that gene vectors can provide. Substantial investments in gene therapy research and development, coupled with increasing government funding and venture capital investments, are accelerating market growth.

The growing number of clinical trials for gene therapies and recent regulatory approvals, such as U.S. FDA approvals for various gene therapy products, have created favorable market conditions. Technological advancements in vector engineering, including improved targeting specificity and reduced immunogenicity, are enhancing therapeutic efficacy and patient safety profiles. However, the market faces significant restraints, primarily the high costs associated with gene vector development and manufacturing, which limit accessibility and commercial viability.

Complex regulatory requirements and lengthy approval processes create barriers for market entry and product commercialization. Safety concerns related to viral vector-induced immune responses, potential insertional mutagenesis, and long-term effects continue to challenge market acceptance. Additionally, technical challenges in vector design, including limited payload capacity and tissue-specific targeting difficulties, restrict therapeutic applications. Nevertheless, substantial opportunities exist within the market landscape.

The expanding applications of gene vectors in treating rare diseases, where limited therapeutic options exist, present lucrative growth prospects. Emerging markets in Asia Pacific and Latin America offer untapped potential due to improving healthcare infrastructure and increasing awareness. Collaborative partnerships between pharmaceutical companies and biotechnology firms are fostering innovation and market expansion. The development of next-generation vectors with improved safety profiles and enhanced delivery capabilities, along with advances in manufacturing technologies that could reduce production costs, represent significant growth opportunities for market participants.

Key Features of the Study

• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global gene vector market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include Lonza Group, Thermo Fisher Scientific, Catalent Inc, Oxford Biomedica, FUJIFILM Diosynth Biotechnologies, Advanced Therapies, LLC., Aldevron, AGC Biologics, SIRION Biotech, FinVector, Merck KGaA, uniQure, Charles River Laboratories, Takara Bio.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global gene vector market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global gene vector market

Market Segmentation

• Vector Type Insights (Revenue, USD Bn, 2021 - 2033)
• Viral Vectors
  • Adenoviral Vectors
  • Adeno-Associated Viral (AAV) Vectors
  • Lentiviral Vectors
  • Gamma-Retroviral Vectors
  • Herpes Simplex Viral (HSV) Vectors
  • Poxviral/Vaccinia Vectors
  • Other Viral Vectors (Sendai, VSV, Baculovirus, etc.)
• Non-Viral Vectors
  • Plasmid DNA Vectors
  • Lipid-Based Nanoparticle (LNP) Vectors
  • Polymeric/Synthetic Nanoparticle Vectors
  • Inorganic Nanoparticle Vectors (gold, silica-based, etc.)
• Payload Type Insights (Revenue, USD Bn, 2021 - 2033)
• DNA Vectors
• RNA Vectors
• siRNA/shRNA Vectors
• CRISPR/Cas Components
• Antisense Oligonucleotides
• mRNA Vectors
• Application Insights (Revenue, USD Bn, 2021 - 2033)
• Gene Replacement Therapy
• Gene Addition/Augmentation Therapy
• Gene Silencing/Knockdown
• Gene Editing (CRISPR, ZFN, TALEN)
• Cell Therapy Manufacturing (CAR-T, engineered NK/T cells)
• Vaccines (prophylactic and therapeutic)
• Research Use Only (preclinical in vitro/in vivo tools)
• Disease Area Insights (Revenue, USD Bn, 2021 - 2033)
• Oncology
• Neurology
• Cardiovascular and Metabolic
• Ophthalmic
• Hematologic and Immunologic
• Infectious Diseases
• Musculoskeletal and Genetic Muscle Disorders
• Dermatology and Wound Healing
• Other Rare Genetic Disorders
• Delivery Route Insights (Revenue, USD Bn, 2021 - 2033)
• Intravenous
• Intramuscular
• Subcutaneous
• Intrathecal
• Intratumoral
• Ocular
• Inhalation
• Others
• Delivery Mode Insights (Revenue, USD Bn, 2021 - 2033)
• In Vivo Delivery
• Ex Vivo Delivery
• End User Insights (Revenue, USD Bn, 2021 - 2033)
• Biopharmaceutical and Biotechnology Companies
• CDMOs/CMOs (Contract Development and Manufacturing Organizations)
• Academic and Research Institutes
• Government and Non-Profit Research Organizations
• Hospital-Based and Specialty Gene Therapy Centers
• Regional Insights (Revenue, USD Bn, 2021 - 2033)
• North America
  • U.S.
  • Canada
• Latin America
  • Brazil
  • Argentina
  • Mexico
  • Rest of Latin America
• Europe
  • Germany
  • U.K.
  • Spain
  • France
  • Italy
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
• Middle East
  • GCC Countries
  • Israel
  • Rest of Middle East
• Africa
  • South Africa
  • North Africa
  • Central Africa
• Key Players Insights
• Lonza Group
• Thermo Fisher Scientific
• Catalent Inc
• Oxford Biomedica
• FUJIFILM Diosynth Biotechnologies
• Advanced Therapies, LLC.
• Aldevron
• AGC Biologics
• SIRION Biotech
• FinVector
• Merck KGaA
• uniQure
• Charles River Laboratories
• Takara Bio

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Global Gene Vector Market, By Vector Type
  • Global Gene Vector Market, By Payload Type
  • Global Gene Vector Market, By Application
  • Global Gene Vector Market, By Disease Area
  • Global Gene Vector Market, By Delivery Route
  • Global Gene Vector Market, By Delivery Mode
  • Global Gene Vector Market, By End User
  • Global Gene Vector Market, By Region

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
• Driver
• Restraint
• Opportunity
• Impact Analysis
• Key Developments
• Regulatory Scenario
• Product Launches/Approvals
• PEST Analysis
• PORTER's Analysis
• Merger and Acquisition Scenario
• Industry Trends

4. Global Gene Vector Market, By Vector Type, 2021 - 2033, (USD Bn)

• Introduction
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2022 - 2033
  • Segment Trends
• Viral Vectors
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
    • Adenoviral Vectors
    • Adeno-Associated Viral (AAV) Vectors
    • Lentiviral Vectors
    • Gamma-Retroviral Vectors
    • Herpes Simplex Viral (HSV) Vectors
    • Poxviral/Vaccinia Vectors
    • Other Viral Vectors (Sendai, VSV, Baculovirus, etc.)
• Non-Viral Vectors
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
    • Plasmid DNA Vectors
    • Lipid-Based Nanoparticle (LNP) Vectors
    • Polymeric/Synthetic Nanoparticle Vectors
    • Inorganic Nanoparticle Vectors (gold, silica-based, etc.)

5. Global Gene Vector Market, By Payload Type, 2021 - 2033, (USD Bn)

• Introduction
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2022 - 2033
  • Segment Trends
• DNA Vectors
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
• RNA Vectors
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
• siRNA/shRNA Vectors
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
• CRISPR/Cas Components
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
• Antisense Oligonucleotides
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
• mRNA Vectors
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)

6. Global Gene Vector Market, By Application, 2021 - 2033, (USD Bn)

• Introduction
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2022 - 2033
  • Segment Trends
• Gene Replacement Therapy
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
• Gene Addition/Augmentation Therapy
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
• Gene Silencing/Knockdown
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
• Gene Editing (CRISPR, ZFN, TALEN)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
• Cell Therapy Manufacturing (CAR-T, engineered NK/T cells)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
• Vaccines (prophylactic and therapeutic)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
• Research Use Only (preclinical in vitro/in vivo tools)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)

7. Global Gene Vector Market, By Disease Area, 2021 - 2033, (USD Bn)

• Introduction
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2022 - 2033
  • Segment Trends
• Oncology
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
• Neurology
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
• Cardiovascular and Metabolic
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
• Ophthalmic
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
• Hematologic and Immunologic
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
• Infectious Diseases
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
• Musculoskeletal and Genetic Muscle Disorders
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
• Dermatology and Wound Healing
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
• Other Rare Genetic Disorders
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)

8. Global Gene Vector Market, By Delivery Route, 2021 - 2033, (USD Bn)

• Introduction
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2022 - 2033
  • Segment Trends
• Intravenous
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
• Intramuscular
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
• Subcutaneous
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
• Intrathecal
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
• Intratumoral
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
• Ocular
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
• Inhalation
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
• Others
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)

9. Global Gene Vector Market, By Delivery Mode, 2021 - 2033, (USD Bn)

• Introduction
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2022 - 2033
  • Segment Trends
• In Vivo Delivery
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
• Ex Vivo Delivery
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)

10. Global Gene Vector Market, By End User, 2021 - 2033, (USD Bn)

• Introduction
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2022 - 2033
  • Segment Trends
• Biopharmaceutical and Biotechnology Companies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
• CDMOs/CMOs (Contract Development and Manufacturing Organizations)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
• Academic and Research Institutes
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
• Government and Non-Profit Research Organizations
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
• Hospital-Based and Specialty Gene Therapy Centers
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)

11. Global Gene Vector Market, By Region, 2021 - 2033, Value (USD Bn)

• Introduction
  • Market Share (%) Analysis, 2026, 2028 & 2033, Value (USD Bn)
  • Market Y-o-Y Growth Analysis (%), 2022 - 2033, Value (USD Bn)
  • Regional Trends
• North America
  • Introduction
  • Market Size and Forecast, By Vector Type, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Payload Type, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Application, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Disease Area, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Delivery Route, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Delivery Mode, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
    • U.S.
    • Canada
• Latin America
  • Introduction
  • Market Size and Forecast, By Vector Type, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Payload Type, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Application, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Disease Area, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Delivery Route, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Delivery Mode, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
• Europe
  • Introduction
  • Market Size and Forecast, By Vector Type, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Payload Type, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Application, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Disease Area, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Delivery Route, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Delivery Mode, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, By Vector Type, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Payload Type, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Application, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Disease Area, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Delivery Route, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Delivery Mode, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
• Middle East
  • Introduction
  • Market Size and Forecast, By Vector Type, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Payload Type, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Application, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Disease Area, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Delivery Route, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Delivery Mode, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
    • GCC Countries
    • Israel
    • Rest of Middle East
• Africa
  • Introduction
  • Market Size and Forecast, By Vector Type, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Payload Type, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Application, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Disease Area, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Delivery Route, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Delivery Mode, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Country/Region, 2021 - 2033, Value (USD Bn)
    • South Africa
    • North Africa
    • Central Africa

12. Competitive Landscape

• Lonza Group
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Thermo Fisher Scientific
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Catalent Inc
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Oxford Biomedica
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• FUJIFILM Diosynth Biotechnologies
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Advanced Therapies, LLC.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Aldevron
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• AGC Biologics
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• SIRION Biotech
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• FinVector
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Merck KGaA
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• uniQure
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Charles River Laboratories
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Takara Bio
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies

13. Analyst Recommendations

• Wheel of Fortune
• Analyst View
• Coherent Opportunity Map

14. References and Research Methodology

• References
• Research Methodology
• About us